Atopic Dermatitis

Panelists discuss how future therapies should aim to provide faster symptom relief than the current 4- to 8-week timeframe, offer longer-lasting depot effects requiring less frequent application, and accelerate the regulatory process for extending safe adult medications to younger pediatric populations.

At Elevate-Derm Fall, Peter Lio, MD, discussed how flexible clinical reasoning and an expanding therapeutic pipeline, particularly hidradenitis suppurativa and atopic dermatitis, are reshaping patient management heading into 2026.

Robert Bissonnette, MD, presented tape-strip transcriptomics detecting meaningful steroid responses after just 1 day of therapy.

Panelists discuss how comprehensive caregiver education forms the foundation of successful treatment, involving dispelling internet misinformation, demonstrating proper application techniques like fingertip units, addressing steroid fears, and establishing realistic expectations about long-term management rather than seeking quick cures.

Panelists discuss how they determine when to escalate to systemic therapies by focusing on patient-reported outcomes rather than clinical appearance alone, asking about flare frequency and typical vs bad days, while emphasizing the importance of continuing topicals alongside systemics with potential for future de-escalation.

Arcutis advances pediatric atopic dermatitis treatment with roflumilast cream, completing enrollment in key INTEGUMENT-INFANT trial.

The exclusive event brought together physician assistants and nurse practitioners from across the country to review complex atopic dermatitis, psoriasis, chronic hand eczema, and hidradenitis suppurativa patient cases.

Panelists discuss how twice-daily dosing represents the biggest adherence challenge and how simplifying regimens from multiple location-specific medications to single versatile treatments significantly improves adherence, with once-daily formulations being much more manageable for busy families.

Panelists discuss how roflumilast demonstrated 25% Investigator’s Global Assessment (IGA) success at 4 weeks in the Integument PED trial with impressive long-term results showing 73% Eczema Area and Severity Index (EASI-75) achievement at 56 weeks, while highlighting its excellent tolerability profile with no black box warning, no folliculitis, and minimal stinging compared with previous phosphodiesterase-4 inhibitors.

Findings suggest immune dysregulation and chronic inflammation in atopic dermatitis may contribute to increased skin cancer susceptibility.

Skin pain in atopic dermatitis significantly impacts quality of life, necessitating its recognition and treatment as a vital symptom for better patient outcomes.

Castle Biosciences’ new test uses molecular signatures from lesional skin to guide systemic therapy decisions in moderate to severe AD.

Discover the latest advancements in atopic dermatitis treatment and patient advocacy during Eczema Awareness Month, shaping future care and quality of life.

Panelists discuss how tapinarof showed strong efficacy in the Adoring trials, with 45% to 46% Investigator’s Global Assessment (IGA) success and 55% to 60% Eczema Area and Severity Index (EASI-75) achievement at 8 weeks. However, they question real-world adherence to daily application over such extended periods and note folliculitis as a notable adverse effect occurring in over 5% of patients.

Panelists discuss how ruxolitinib cream demonstrated impressive efficacy in the TRU83 trial, with over 50% of patients achieving near-complete clearance at 8 weeks using the 1.5% formulation, while acknowledging that the Janus kinase (JAK) inhibitor’s broad mechanism makes its effectiveness unsurprising despite concerns about the boxed warning.

Christopher Bunick, MD, PhD, urged clinicians to move beyond therapeutic inertia and transition patients to advanced systemic therapies.

Arcutis has expanded roflumilast cream in the US, a steroid-free treatment for mild to moderate AD in young children.

Incyte reveals promising TRuE-AD4 trial results for ruxolitinib cream, showcasing its effectiveness and safety for adults with moderate atopic dermatitis.

At Fall Clinical 2025, Mona Shahriari, MD, presented highlights on the role of IL-13 inhibitors, such as dupilumab, tralokinumab, and lebrikizumab, in managing atopic dermatitis across severities.

James Del Rosso, DO; April Armstrong, MD, MPH; Mark Nestor, MD, PhD; Mark Lebwohl, MD; Linda Stein Gold, MD; and Darrell Rigel, MD, MS, presented some of the biggest updates in dermatology to close out the year.

At a recent Dermatology Times Case-Based Roundtable event, John Browning, MD, led a discussion on evolving strategies for atopic dermatitis management.

The findings reinforce dupilumab as a safe, long-term cornerstone therapy for pediatric AD, with emerging flexibility in treatment scheduling.

Experts discuss the OX40 pathway's potential to transform atopic dermatitis treatment, addressing unmet needs and promising new therapies for better patient outcomes.

In the ARCADIA LTE, nemolizumab maintained significant and progressive improvements in skin and itch outcomes for up to 104 weeks.

Mobile app SkinTracker enhances atopic dermatitis care through remote assessments, proving effective and convenient for patients while saving costs.